linjc16/ctgov huggingface dataset:
Myeloma Novel Drug Discovery Ver 1.2

Study Overview
=================
Brief Summary
-----------------
Myeloma is a bone marrow cancer with over 5000 patients diagnosed in the UK each year. Researchers are committed to improving understanding of myeloma and developing more effective treatments with fewer side effects in order to improve patient outcomes. In order to do this, researchers are collecting samples of blood and bone marrow to test the activity of potential new treatments in the laboratory and to understand what may be the cause of some treatments not working.

Official Title
-----------------
Investigation of the Activity of Novel Compounds for the Treatment of Myeloma and Mechanisms of Drug Resistance to Current Therapies

Conditions
-----------------
Multiple Myeloma

Intervention / Treatment
-----------------
* Other: Observational study - sample collection only.


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Participants who have a diagnosis, or suspected diagnosis, of myeloma or related plasma cell disorder Participants who are undergoing a peripheral blood or bone marrow aspirate sampling for diagnostic, staging or follow-up purposes, before, whilst or after receiving anti-myeloma treatment Participants aged 18 years of age or above Participants willing to consent to an additional sample being taken at the time of their peripheral blood or bone marrow aspirate sampling Exclusion Criteria: Participants unable to provide consent Participants with known active infectious diseases (e.g. HIV, Hepatitis B/C, COVID) that pose a risk to the use of the sample in the laboratory

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Participants with a diagnosis, or suspected diagnosis, of myeloma or related plasma cell disorder<br>Participants who are undergoing peripheral blood or bone marrow aspirate sampling for diagnostic, staging or follow-up purposes, before, whilst or after receiving anti-myeloma treatment will be approached to collect additional samples for research. | Other: Observational study - sample collection only.<br>* No intervention - blood and/or bone marrow sample collection only<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cell viability | Myeloma cell viability when incubated with standard of care and novel compounds. | 12 months |
Comparison of Therapeutic Efficacy Between Intralesional Bleomycin and Cryotherapy in Plantar Warts

Study Overview
=================
Brief Summary
-----------------
A randomized control trial to compare the efficacy difference between intralesional bleomycin and cryotherapy in treating plantar warts.

Detailed Description
-----------------
In spite of many available studies on bleomycin and cryotherapy in treating warts, little head-to-head research is carried out to compare the efficacy of these treatments. This study shows clear difference in the clearance of warts treated with intralesional bleomycin and cryotherapy.

Official Title
-----------------
Comparison of Therapeutic Efficacy Between Intralesional Bleomycin and Cryotherapy in Plantar Warts

Conditions
-----------------
Viral Wart

Intervention / Treatment
-----------------
* Procedure: COMPARISON OF THERAPEUTIC EFFICACY BETWEEN INTRALESIONAL BLEOMYCIN AND CRYOTHERAPY IN PLANTAR WARTS


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria -healthy individuals of both genders between 18 to 50 years Exclusion Criteria Pregnant and Lactating women history of vascular diseases/ chilblains Immunocompromised patients Treated previously for warts

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: Randomized Control Trial (RCT)
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: BLEOMYCIN<br>COMPARISON OF THERAPEUTIC EFFICACY BETWEEN INTRALESIONAL BLEOMYCIN AND CRYOTHERAPY IN PLANTAR WARTS | Procedure: COMPARISON OF THERAPEUTIC EFFICACY BETWEEN INTRALESIONAL BLEOMYCIN AND CRYOTHERAPY IN PLANTAR WARTS<br>* comparison of therapeutic efficacy between intralesional bleomycin and cryotherapy in plantar warts<br>|
| Active Comparator: CRYOTHERAPY<br>COMPARISON OF THERAPEUTIC EFFICACY BETWEEN INTRALESIONAL BLEOMYCIN AND CRYOTHERAPY IN PLANTAR WARTS | Procedure: COMPARISON OF THERAPEUTIC EFFICACY BETWEEN INTRALESIONAL BLEOMYCIN AND CRYOTHERAPY IN PLANTAR WARTS<br>* comparison of therapeutic efficacy between intralesional bleomycin and cryotherapy in plantar warts<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| comparative effecacy of intra lesional bleomycin vs cryotherapy in treating plantar warts within 30 days of treatment | Intralesional bleomycin is more effective than cryotherapy in treating plantar warts within | 30 days of treatment |
Description of Changes in NIRS as a Function of Ductus Arteriosus Status in Very Premature Babies Born Before 32 WG at the DIJON University Hospital

Study Overview
=================
Brief Summary
-----------------
Monitoring patent ductus arteriosus is currently performed using echocardiography, an operator-dependent examination which requires holding the child on their back and which is potentially time-consuming. This test is usually carried out on days 2, 4 and 7 after birth. NIRS (near-infrared spectroscopy) is a non-invasive method of monitoring tissue oxygen saturation using infrared light. The aim of the study was to investigate an association between cerebral and renal NIRS data and ductus arteriosus status obtained by echocardiography.

Official Title
-----------------
Description of Changes in NIRS as a Function of Ductus Arteriosus Status in Very Premature Babies Born Before 32 WG at the DIJON University Hospital: Exploratory Prospective, Monocentric, Observational, Descriptive Study

Conditions
-----------------
Extremely Premature Newborn (Born Before 32 Weeks' Gestation)

Intervention / Treatment
-----------------
* Other: Collection of brain and kidney NIRS measurements
* Other: echocardiography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Parent who has agreed to participate in the study Very premature newborn (born before 32 weeks' gestation) Hospitalised in the Neonatal Intensive Care Unit at Dijon University Hospital Before 48 hours of life Exclusion Criteria: Newborn with congenital heart disease Newborn with a congenital renal anomaly Newborn with polymalformative syndrome Newborn with a skin anomaly Newborn with severe circulatory failure unrelated to the ductus arteriosus

Ages Eligible for Study
-----------------
Maximum Age: 48 Hours

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Extremely premature newborn<br>(born before 32 weeks' gestation) | Other: Collection of brain and kidney NIRS measurements<br>* (recorded continuously) by a person not involved in the study 30 minutes before echocardiography was performed<br>Other: echocardiography<br>* on day 2, day 4 and day 7 of life<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The ultrasound status of the ductus arteriosus | (haemodynamically significant open, non-haemodynamically significant open, closed) | On day 2, day 4 and day 7 of life |
Functional Outcome After Minimally Invasive Pyeloplasty for Adult Patients With UPJO

Study Overview
=================
Brief Summary
-----------------
an intervention study on adult patients with uretero-pelvic junction obstruction (UPJO) due to crossing vessels would be managed either through classic dismembered pyeloplasty or vascular hitch.

Detailed Description
-----------------
in recent studies, some patients with crossing vessels UPJO could be managed by vascular displacement of these vessels, what is named as vascular hitch or vasculopexy in a way to avoid classic dismembered technique. this newer technique is supposed to provide comparable results to the classic technique but with lesser operative time and shorter hospital stay. in the era of minimally invasive procedures, robotic assisted or laparoscopic vascular hitch could provide many advantages over the classic open technique.

Official Title
-----------------
Functional Outcome After Laparoscopic and Robot Assisted Management of Uretero-pelvic Junction Obstruction Disease Caused by Crossing Vessels for Adult Patients

Conditions
-----------------
Ureteropelvic Junction Obstruction

Intervention / Treatment
-----------------
* Procedure: pyeloplasty


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: all patients with UPJO above 18 years UPJO caused by crossing vessels confirmed by CT angiography Symptomatic UPJO Exclusion Criteria: recurrent UPJO after a previous trial of open repair , secondary UPJO after open renal surgery. UPJO in non functioning kidney

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: randomized intervention study
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: vascular hitch<br>displacement of the lower polar crossing vessels causing the UPJO | Procedure: pyeloplasty<br>* repair of the uPJO<br>|
| Active Comparator: Dismembered pyeloplasty<br>classic Anderson-Hynes procedure | Procedure: pyeloplasty<br>* repair of the uPJO<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| comparing the two techniques regarding the success rate | both techniques are supposed to have similar results | 2 years |
Prognostic Value of Pre-therapy 18F-FDG PET/CT for the Outcome of 18 FDG PET-guided SIB-IMRT in Patients With Head and Neck Cancer

Study Overview
=================
Brief Summary
-----------------
Head and neck cancer is the fifth most common cancer and represents 5% in the world. Selecting patients for the most appropriate treatment remains difficult. Approximately 60-65% of patients undergo surgery followed or not by radiotherapy. Patients with early stage disease (I-II) are treated with one treatment modality (surgery or radiotherapy), while patients with more advanced stage disease (III-IV) receive multimodal treatment (surgery together with associated radiotherapy or less to chemotherapy). PET/CT plays a fundamental role in the management of head and neck cancer patients. This investigation is indicated for staging, especially in patients with disease in advanced stages, for evaluating the response to therapy and for looking for recurrences as it is more accurate in distinguishing scar tissue from neoplasm. The objective of this retrospective study is to evaluate the prognostic value of PET/CT in predicting the outcome of patients undergoing SlB-IMRT/intensity modulated radiotherapy). The study proposed here involves the retrospective recruitment of patients who have performed a PET/CT investigation with 18F-FDG (fluorodeoxyglucose) at the U.O. of HSR Nuclear Medicine in the staging and treatment planning phase, between 2005 and 2011. The inclusion condition of the patients was their PET/CT evaluation (planning and treatment) using the DSTE PET/CT system installed at the U.O. of Nuclear Medicine HSR on which, in the presence of homogeneous lesions. a particular correction technique is applicable, developed and validated previously by the research group, which allows possible metabolic markers to be extracted from the lesions in a quantitatively accurate way.

Official Title
-----------------
Prognostic Value of Pre-therapy 18F-FDG PET/CT for the Outcome of 18 FDG PET-guided SIB-IMRT in Patients With Head and Neck Cancer

Conditions
-----------------
Head and Neck Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients suffering from head and neck cancer; patients who underwent PET-CT with 18F-FDG. Exclusion Criteria: patients <18 years

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PET-CT investigation with 18F-FDG for staging patients with head and neck cancer. | Patients underwent 18 F-FDG PET-CT during staging and treatment planning. They subsequently underwent Intensity Modulated Radiotherapy (IMRT) with a simultaneous boost (SIB) on a region highlighted by PET-CT as metabolically active. | 1 year |
Prospective Cohort Observational Study of Placenta Accreta Spectrum Disorders

Study Overview
=================
Brief Summary
-----------------
The incidence of placenta accreta spectrum disorders has shown an increasing trend worldwide due to the increase of cesarean section rate. Research on the outcomes of placenta accreta spectrum disorders primarily relies on retrospective analysis. The aim of this study was to establish a prospective, multicenter cohort in China in order to conduct further investigations on the clinical features, predictive capabilities, diagnostic methods, and pathogenesis of placenta accreta spectrum disorders.

Official Title
-----------------
Prospective Cohort Observational Study of Placenta Accreta Spectrum Disorders

Conditions
-----------------
Placenta Accreta Spectrum Disorders,Previous Cesarean Section

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Pregnant women aged 18-45; at least one previous cesarean section ,regular antenatal examination and plan to give birth at research center sign informed consent Exclusion Criteria: Irregular antenatal examination; Twins; Autoimmune diseases; Prepregnancy hypertension; Prepregnancy diabetes mellitus; Inheritance Sexual diseases; tumor; Abnormal liver and kidney function in early pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of placenta accreta spectrum disorders |  | baseline | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Preterm delivery Preterm delivery |  | baseline | 
| Blood lost during delivery |  | baseline | 
| Blood loss in the first 24 hours of delivery |  | baseline | 
| hysterectomy |  | baseline | 
| Blood transfusion |  | baseline | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
placenta accreta spectrum disorders；Previous cesarean section
Pain Improvement After Ultrasound Guided Continuous Radio Frequency 60 Degree for Plantar Fasciitis

Study Overview
=================
Brief Summary
-----------------
detailed changes after ultrasound guided cry for plantar fasciitis in regard pain score and plantar fascia AP diameter in ultrasound scan pre and 30 days post operation

Official Title
-----------------
Decrease in Pain Score After Ultrasound Guided CRF for Chronic Plantar Fasciitis Not Responding to Treatment in Addition to Ultrasound Changes

Conditions
-----------------
Plantar Fascitis

Intervention / Treatment
-----------------
* Procedure: ultrasound guided 60 degree CRF for plantar fasciitis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: chronic plantar fasciitis not responding to treatment not responding to classical injection Exclusion Criteria: torn plantar fascia

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Interventional Model Description: chronic plantar fasciitis not responding to classical injection by steroid or regenerative therapy
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: plantar fasciitis<br> | Procedure: ultrasound guided 60 degree CRF for plantar fasciitis<br>* ultrasound guided plantar fascia CRF for chronic conditions not responding to treatment<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| reduction in pain score | reduction in pain score immediate and 1 week and 2 month according to NAS | 6 months |
Examining the Effects of a Remote Pulmonary Rehabilitation Program in the Severe Asthma Population.

Study Overview
=================
Brief Summary
-----------------
This is a randomized control trial evaluating the effect of a novel mobile application-delivered pulmonary rehabilitation program in adult severe asthma patients. The intervention will include eight weeks of exercise videos that progress in difficulty, as well as asthma-specific educational content. The primary outcome measure is change in functional exercise capacity as measured by six-minute walk distance. Secondary outcome measures will include evaluation of overall feasibility, and change in CPET parameters such as VO2max. Change in asthma control questionnaire (ACQ), asthma quality of life questionnaire (AQLQ) and PRAISE self-efficacy score will also be evaluated.

Official Title
-----------------
STAPLE (Severe asThmA PuLmonary rEhab): Examining the Effects of a Remote Pulmonary Rehabilitation Program in the Severe Asthma Population.

Conditions
-----------------
Asthma

Intervention / Treatment
-----------------
* Behavioral: Pulmonary rehab program
* Behavioral: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adults aged 18 years and older with a diagnosis of asthma by a respirologist. They must have severe disease defined by GINA severity classification. Participants must have access to a smartphone or internet browser to allow access to study content. Exclusion Criteria: Exclusion criteria include comorbid cardiopulmonary or musculoskeletal conditions that may impact exercise tolerance in accordance with the American Thoracic Society CPET guidelines

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Physical activity intervention<br>8 week virtual pulmonary rehab program including breathing exercises and educational messages. | Behavioral: Pulmonary rehab program<br>* Exercise videos, breathing exercises, and educational messages delivered virtually<br>|
| Placebo Comparator: Placebo<br>Breathing exercises and educational messages | Behavioral: Placebo<br>* Breathing exercises and educational messages<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| CPET | VO2max | After 8 weeks of intervention |
Trial for Surgical Treatment of Reducible Atlantoaxial Dislocation

Study Overview
=================
Brief Summary
-----------------
The management of reducible atlantoaxial dislocation associated is challenging. Direct posterior distraction technique we proposed in 2010 could achieve satisfactory reduction. In 2020, we modified this technique and proposed a posterior intra-articular distraction technique. The intra-articular distraction technique could theoretically achieve satisfactory reduction and fusion. However, its superiority has not been proven. Therefore, we design a RCT study to compare the reduction rate and fusion rate of different strategies.

Official Title
-----------------
A Randomized Controlled Trial for Surgical Treatment of Reducible Atlantoaxial Dislocation

Conditions
-----------------
Atlantoaxial Dislocation

Intervention / Treatment
-----------------
* Device: Intra-articular Cages


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: CT indicated atlantoaxial dislocation Agree with the operation plan Agree to be followed up Exclusion Criteria: The pathology is traumatic or RA Underwent operations in occipital-cervical region before With mortal diseases Without ability to sign papers

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Intra-articular Group<br>Posterior intra-articular distraction and fusion | Device: Intra-articular Cages<br>* Using reduction using posterior intra-articular distraction and fusion technique with cages.<br>|
| No Intervention: Posterior Group<br>Posterior direct distraction and fusion | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Fusion Rates | Atlantoaixal fusion rates | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Japanese Orthopaedic Association Scores | 0-17 Scores | 12 months | 
| Visual Analogue Scale | 0-10 Scores | 12 months | 
| Neck Disability Index | 0-5 Scores | 12 months |